Science
Experimental Pill Targets 'Undruggable' KRAS Mutations in Pancreatic Cancer
A new drug from Revolution Medicines uses molecular glue to bind with KRAS subtypes, targeting mutations long considered impossible to treat.
Topic
1 story on pancreatic-cancer, across Science.
A new drug from Revolution Medicines uses molecular glue to bind with KRAS subtypes, targeting mutations long considered impossible to treat.